Xigad L 10 Tablet is a combination oral antidiabetic medication containing Empagliflozin 10 mg and Linagliptin 5 mg, indicated for the management of type 2 diabetes mellitus. Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting urinary glucose excretion and thereby lowering blood glucose levels. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. The dual mechanism of action targets hyperglycemia through complementary pathways, improving glycemic control when diet and exercise alone are insufficient. Xigad L 10 is typically administered once daily, with or without food, and dosage adjustments may be necessary based on renal function and individual patient response. Clinical studies have demonstrated its efficacy in reducing HbA1c levels and fasting plasma glucose with a favorable safety profile. Common adverse effects may include urinary tract infections, nasopharyngitis, and hypoglycemia, particularly when used concomitantly with insulin or sulfonylureas. Caution is advised in patients with renal impairment, volume depletion, or a history of pancreatitis. Regular monitoring of renal function, blood glucose, and potential side effects is recommended during therapy with Xigad L 10 Tablet.